UpcomingCancerInfection & Immunity
Learning from immune related adverse events (toxicity) to improve treatment with immune checkpoint inhibitors for cancer patients of the future.
About this grant
This summary is based on the grant title only — the full abstract was not available.
Research project funded by MRF at University of Birmingham.
View the original record at the funder ↗
Researchers
Claire Palles (EPMC Awardee)
Related Research
Grants with similar aims, by meaning.
Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity
Understanding immune-related toxicities through multifacet profiling
ICI Genetics: Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity (ICI GENETICS)
Investigating Regulatory B cells as determinants of immune-related adverse events following checkpoint blockade therapy
Advancing immunotherapy by analysing inhibitory receptor expression and function ex vivo
Original classification
Impact of Cancer and Cancer Care on Human Biology and Health 2025Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.Is something wrong? Let us know